Supriya Lifescience IPO Basis of Allotment

SUPRIYA LIFESCIENCE LIMITED

Our Company was incorporated as 'Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of 'M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. Our Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC. For further details, including details relating to changes in the registered office see "History and Certain Corporate Matters" on page 154 of the prospectus ("Prospectus").

Our Company has filed the Prospectus dated December 21, 2021 with the RoC, (the "Prospectus") and the Equity Shares are proposed to be listed on the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and the trading will commence on December 28, 2021.

INITIAL PUBLIC OFFERING OF 25,547,445 EQUITY SHARES OF FACE VALUE OF RS. 2 EACH ("EQUITY SHARES") OF SUPRIYA LIFESCIENCE LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 274 PER EQUITY SHARE ("OFFER PRICE") AGGREGATING TO RS. 7,000 MILLION, COMPRISING A FRESH ISSUE OF 7,299,270 EQUITY SHARES AGGREGATING TO RS. 2,000 MILLION ("FRESH ISSUE ") AND AN OFFER FOR SALE OF 18,248,175 EQUITY SHARES AGGREGATING TO RS. 5,000 MILLION BY SATISH WAMAN WAGH (THE "PROMOTER SELLING SHAREHOLDER") (THE "OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER"). THE OFFER WILL CONSTITUTE 31.74% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL

This Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBIICDR Regulations"). This Offer was made through the Book Building Process in accordance with Regulation 6(2) of the SEBIICDR Regulations wherein not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion''), provided that our Company and the Promoter Selling Shareholder in consultation with the BRLMs allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). One-third of the Anchor Investor Portion was reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price, 5% of the Net QIB Portion was available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to, QIBs, the Bid Amounts received by our Company will be refunded Further not more than 15% of the Offer was available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Offer was made available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, were mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ('ASBA') process by providing details of their respective ASBA Account, which will be blocked by the Self Certified Syndicate Banks ("SCSBs"), or through the UPI Mechanism. Anchor Investors were not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "Offer Procedure" beginning on page 323 of the Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, December 15, 2021. The company received 18 applications from 18 anchor investors for 12,773,646 equity shares. The Anchor investor price was finalized at Rs. 274 per Equity Share. A total of 11,496,351 shares were allocated under the Anchor Investor Portion aggregating to Rs. 3,150,000,174.

The Offer received 2,052,574 applications for 1,017,300,384 Equity Shares (prior to technical rejections) resulting in 39.8200 times subscription. The details of the applications received in the Offer from various categories are as under: (before technical rejections):

Final Demand

A summary of the final demand as at different Bid prices is as under

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being the BSE on December 23, 2021.

A. Allotment to Retail Individual Bidders (after technical rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of Rs. 274 per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 49.3126 times. The total number of Equity Shares Allotted In Retail Portion is 2,554,744 Equity Shares to 47,310 successful Retail Individual Bidder. The category-wise details of the Basis of Allotment are as under:

Please Note. 1 additional Share was allotted to 4 Allottees from amongst 2,732 Successful Applicants from the categories 108-702 (i.e. excluding successful applicants from Category 54) in the ratio of 4:2,732

B. Allotment to Non-Institutional Bidders (After Technical Rejections)

The Basis of Allotment lo the Non-Institutional Bidders, who have bid at the Offer Price of Rs. 274 per Equity Share or above, was finalized in consultation with the BSE. The Non-Institutional Portion has been subscribed to the extent of 160.4212 times. The total number of Equity Shares Allotted in this category is 3,832,116 Equity Shares to 3.110 successful Non- Institutional Bidders. The category-wise details of the Basis of Allotment are as under: (Sample)

C. Allotment to QIBs

Allotment to QIBs, who have Bid at the Offer Price of Rs. 274 per Equity Share or above, has been done on a proportionate basis in consultation with the BSE. This category has been subscribed to the extent of 32.7388 times of QIB Portion. As per the SEBIICDR Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., 383,212 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e. 7,281,022 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 7,684,234 Equity Shares, which were allotted to 82 successful QIB Bidders. The category-wise details of the Basis of Allotment are as under:

D. Allotment to Anchor Investors

The Company and the Selling Shareholders, in consultation with the BRLMs, have allocated 11,496,351 Equity Shares to 18 Anchor Investors (through 18 Applications) at the Anchor Investor Offer Price of Rs. 274 per Equity Share in accordance with the SEBIICDR Regulations. This represents 60% of the QIB Portion.

The IPO Committee of our Company on December 23, 2021 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum- Intimations and/or notices will be dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Offer Account have been issued on December 23, 2021 and payment to non-Syndicate brokers have been issued on December 24, 2021, in case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on December 24, 2021 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with NSE and BSE on December 24, 2021. The Company has received listing and trading approval from NSE and BSE and the trading will commence on December 28, 2021.

Note. All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus. Percentage figures have been rounded off to two decimal places.

INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, Link Intime India Private Limited at www.linkintime.co.in

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

Link Intime India Private Limited

C-101, 247 Park, 1st Floor, L B.S Marg, Vikhroli West, Mumbai - 400 083, Maharashtra, India

Tel: +91 22 4918 6200

E-mail: supriyalifeipo@linkintime.co.in

Website: www.linkintime.co.in

Contact Person: Shanti Gopalkrishnan

SEBI Registration No.: INR000004058

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SUPRIYA LIFESCIENCE LIMITED.

Supriya Lifescience Limited has filed the Prospectus dated December 21, 2021. The Prospectus is available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e., ICICI Securities Limited and Axis Capital Limited at www.icicisecurities.com and www.axiscapital.co.in, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 26 of the Prospectus Potential Bidders should not rely on the DRHP Filed with SEBI for making any Investment decision.

The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'Securities Act') or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable US, state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in 'offshore transactions' in reliance on Regulation S and the applicable laws of each jurisdictions where such offers and sales are made. There will be no public offering in the United States.